🔍

Onesource Specialty Pharma Limited (ONESOURCE)

📊 NSE: ONESOURCE 🏢 Miscellaneous 📅 Last Updated: 12/14/2025 10:42

📢 Recent Corporate Announcements

OneSource Specialty Pharma Uploads Investor Presentation for Analyst Meet on Sept 3, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Sep 2026, 12:38 PM

OneSource Specialty Pharma Limited has informed the exchanges that it uploaded its latest Investor Presentation on its website on September 03, 2026. This coincides with the Analyst and Institutional Group Investor meeting scheduled for the same day at its Unit II manufacturing facility in Doddaballapura, Bengaluru. The document itself is a standard intimation covering the website link and meeting reference without disclosing specific new financial metrics directly in the notice.

Intimation of latest Investor Presentation uploaded on September 03, 2026
Analyst/Institutional Group Investor meeting held on September 03, 2026
Meeting conducted on-site at Manufacturing Facility (Unit II) in Doddaballapura, Bengaluru
Prior intimation regarding the meeting was submitted on August 31, 2026

💡 Investors should review the updated investor presentation on the company's website to monitor commentary on CDMO contract ramp-ups, GLP-1 commercial service agreements, and capacity utilization across its facilities.

OneSource Specialty Pharma Submits FY26 BRSR Report with 70.8% Export Revenue Share

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 31 Aug 2026, 10:36 PM

OneSource Specialty Pharma Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for FY26 pursuant to SEBI LODR regulations. The disclosure highlights standalone revenue of ₹14,204 million (₹1,420.4 crore) and net worth of ₹59,430.95 million (₹5,943.1 crore), with exports contributing 70.80% of total standalone turnover. The company operates 5 manufacturing plants in Bengaluru (4 owned, 1 loan licensed) and serves markets across 20+ Indian states and over 30 countries. The report carries reasonable assurance on core ESG indicators from SGS India Private Limited.

Export contribution stood at 70.80% of total standalone turnover (including other income) across >30 countries
Reported standalone turnover of ₹14,204 million and net worth of ₹59,430.95 million for FY26
Total workforce includes 1,200 permanent employees and 1,089 workers (474 permanent and 615 contractual)
Operations comprise 5 manufacturing facilities in Bengaluru (4 owned, 1 under loan license) and 3 international offices

💡 This is a statutory ESG filing with no impact on near-term financial estimates; track upcoming quarterly operating results and progress on CDMO capacity utilization.

OneSource Convenes 19th AGM on Sep 23, 2026; Publishes FY26 Integrated Annual Report

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 31 Aug 2026, 08:29 PM

Onesource Specialty Pharma Limited has issued notice for its 19th Annual General Meeting (2nd AGM post-listing) scheduled for September 23, 2026, via video conferencing. The company also released its Integrated Annual Report for FY26 detailing operations and strategic progress. Key disclosures in the report highlight an ongoing US$ 100 million capex plan (80% committed) and commercialisation of a second cartridge line slated for Q2 FY27. Against a TTM revenue of ₹1,544 Cr and market cap of ₹17,691 Cr, the submission reflects standard corporate governance reporting.

19th Annual General Meeting scheduled for Wednesday, September 23, 2026, at 17:00 IST via VC/OAVM.
Integrated Annual Report outlines US$ 100 million announced capex program, of which 80% is committed.
Target commercialisation for the second cartridge line is set for Q2 FY27.
Report highlights an installed softgel capacity of 2.4 billion units and 50+ DDC projects across 80+ global customers.

💡 Track voting outcomes and shareholder resolutions post-AGM on September 23, 2026, along with commercialisation milestones for cartridge lines in FY27.

OneSource Specialty Pharma Schedules Physical Analyst & Investor Meeting on September 3, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 31 Aug 2026, 06:52 PM

OneSource Specialty Pharma Limited has notified exchanges of a physical Group Investor Meeting scheduled for Thursday, September 3, 2026. The meeting will be held on-site at the company's Unit 2 manufacturing facility in Doddaballapura, Bengaluru Rural. Management will discuss publicly available information including business overview, strategy, and growth outlook, with no unpublished price-sensitive information (UPSI) being shared.

Meeting Date: Thursday, September 03, 2026
Meeting Type: Group Investor Meeting (Physical)
Venue: OneSource Unit 2 Manufacturing Facility, Doddaballapura, Bengaluru Rural District
Agenda: Discussion of publicly available business overview, strategy, and industry trends with no UPSI

💡 Track subsequent post-meet presentation filings or audio/transcript disclosures for any incremental color on facility utilization and CDMO order momentum.

India Ratings Upgrades Onesource to 'IND A'/Positive on Rs 1,553.76 Cr Bank Facilities

🟢 POSITIVE ⭐ 7/10

OTHER 📅 18 Aug 2026, 01:17 PM

India Ratings & Research (Ind-Ra) has upgraded Onesource Specialty Pharma's long-term bank loan rating to 'IND A' from 'IND A-' with a Positive outlook, while affirming the short-term rating at 'IND A1'. The rating covers existing facilities of INR 11,250.51 million (~Rs 1,125.05 Cr) alongside newly assigned limits of INR 4,287.08 million (~Rs 428.71 Cr), totaling Rs 1,553.76 Cr. The agency attributed the upgrade to the commercialisation of its drug-device combination (DDC) platform and expanding commercial GLP-1 supplies, signaling a transition toward a stable, commercial supply-led CDMO model.

Long-term bank loan rating upgraded to 'IND A' with Positive Outlook from 'IND A-'; short-term rating affirmed at 'IND A1'
Total rated bank facilities expand to INR 15,537.59 million (~Rs 1,553.76 Cr), including INR 4,287.08 million of newly assigned limits
Total rated facilities cover ~103% of the company's existing debt load of Rs 1,504 Cr
Upgrade driven by ramp-up in commercial GLP-1 supplies and transition to multi-year commercial supply agreements (CSAs)

💡 Track the quarterly ramp-up in revenue from GLP-1 commercial supply agreements and watch for borrowing cost reductions in upcoming debt servicing metrics.

Q1 FY27: 37% Revenue Growth to ₹449 Cr; OneSource Targets $400M Revenue by FY28

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 31 Jul 2026, 12:55 PM

OneSource Specialty Pharma reported a strong Q1 FY27 with revenue of ₹449 cr, up 37% YoY, and EBITDA of ₹123.3 cr, up 39% YoY. Growth was primarily driven by the commercial launch of semaglutide (GLP-1) in Canada and India, where the company now manufactures over 40% of the generic pens market. Management reiterated its FY28 guidance of $400 million in organic revenue with 40% EBITDA margins, supported by a $100 million capex plan. A second cartridge line is set for commercialization this quarter, which will double sterile production capacity.

Revenue grew 37% YoY to ₹449 cr in Q1 FY27, driven by GLP-1 commercialization and new MSA contracts.
EBITDA increased 39% YoY to ₹123.3 cr, representing a 34% sequential growth over the previous quarter.
The company manufactures >40% of the generic GLP-1 pens market currently sold in India.
The RFP (Request for Proposal) funnel has expanded to 4x its size compared to one year ago.
Management reiterated FY28 targets of $400 million revenue and 40% EBITDA margins.

💡 Monitor the successful ramp-up of the second cartridge line in Q2 FY27 and the execution of the $100 million capex plan to see if the company stays on track for its ambitious FY28 targets.

Management Change: Global Head of Injectables Resigns; New HR Head Designated SMP

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 27 Jul 2026, 07:04 PM

OneSource Specialty Pharma has announced the resignation of Ravi Kumar, Global Head of Injectables and Head of Corporate Strategy, effective July 24, 2026. This exit is significant as the company is currently restructuring to combine the CDMO businesses of Strides, Steriscience, and OneSource, with injectables being a core growth pillar. Simultaneously, Preeti Kalra, who has over 25 years of experience in the Biopharma and IT sectors, has been designated as a Senior Management Personnel (SMP) in her capacity as Head of Human Resources. The company reported a TTM revenue of ₹1,422 Cr and is currently loss-making at the PAT level (₹-49 Cr).

Ravi Kumar resigned as Global Head – Injectables and Head of Corporate Strategy effective July 24, 2026.
Preeti Kalra designated as SMP effective July 24, 2026, bringing 25+ years of leadership experience.
Company maintains 7 manufacturing facilities, with 4 being US FDA approved.
Current installed capacity for the Sterile Injectables business stands at 40 million units.
Restructuring involves combining CDMO businesses and a Softgel hive-off that reduced debt by ₹280 Cr.

💡 Investors should monitor the appointment of a successor for the Global Head of Injectables and Strategy role, as this position is critical for the execution of the integrated CDMO model. Watch for updates on the completion of the planned capacity expansion in CY 2026.

OneSource Specialty Pharma Releases Q1 FY27 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Jul 2026, 03:02 PM

OneSource Specialty Pharma has released the audio recording of its earnings call for the quarter ended June 30, 2026 (Q1 FY27). The call, held on July 25, 2026, provides management commentary on the company's performance and its integrated CDMO model. With a TTM revenue of ₹1,422 Cr and a market cap of ₹12,657 Cr, the company is currently navigating a restructuring phase to combine CDMO businesses from Strides and Steriscience.

Earnings call conducted on July 25, 2026, at 10:00 hrs IST regarding Q1 FY27 results.
Company operates 7 manufacturing facilities, with 4 being USFDA approved as per recent context.
TTM revenue stands at ₹1,422 Cr with an operating profit margin of 21.3%.
Management previously indicated a target of 12% growth and 26 new RFP wins in a single quarter.

💡 Investors should review the recording for updates on the GLP-1 launch timeline and the progress of the restructuring involving Strides and Steriscience.

2,900 Equity Shares Allotted Under ESOP 2021 at Rs 278 Per Share

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Jul 2026, 10:39 PM

OneSource Specialty Pharma Limited has allotted 2,900 equity shares to employees following the exercise of vested options under its 2021 ESOP plan. The shares were issued at an exercise price of Rs 278 per share, which is a significant discount to the current market price of Rs 1,653.9. This allotment results in a negligible dilution of approximately 0.0025% to the existing equity base. The total paid-up share capital has marginally increased to 11,46,72,891 shares.

Allotment of 2,900 equity shares of face value Rs 1 each on July 24, 2026
Exercise price fixed at Rs 278 per share, including a premium of Rs 277
Total paid-up share capital increased from 11,46,69,991 to 11,46,72,891 shares
The allotment represents a negligible dilution of ~0.0025% of the total equity

💡 No action is required as this is a routine administrative allotment. Investors should focus on the upcoming restructuring and CDMO business integration mentioned in previous filings.

37% Revenue Growth in Q1FY27; OneSource Reports ₹449 Cr Revenue and 27.5% EBITDA Margin

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 24 Jul 2026, 09:19 PM

OneSource Specialty Pharma reported a strong start to FY27 with revenue growing 37% YoY to ₹449 crore, driven by the commercial launch of semaglutide in Canada and India. EBITDA rose 39% YoY to ₹123.3 crore, with margins expanding significantly by 600 bps QoQ to 27.5% due to operating leverage. The company reaffirmed its ambitious FY28 guidance of $400 million in organic revenue (approx. ₹3,780 cr) and 40% EBITDA margins. Key operational progress includes the upcoming commercialization of a second cartridge line in Q2 and the addition of 6 new customers, bringing the total to over 80.

Revenue increased 37% YoY to ₹4,490 million (₹449 cr) for Q1FY27.
EBITDA margins expanded to 27.5%, representing a 600 bps improvement over the previous quarter.
Adjusted PAT grew 72% YoY to ₹637 million, excluding exceptional items and amortization.
Biologics RFP funnel grew 4x compared to FY25 levels, indicating strong future pipeline visibility.
Reaffirmed FY28 organic revenue guidance of $400 million with a 40% steady-state EBITDA margin.

💡 Monitor the successful commercialization of the second cartridge line in Q2FY27 and the conversion of the expanded biologics RFP funnel into firm Master Service Agreements (MSAs).

Management Change: Global Head of Injectables Resigns; Head of HR Designated as SMP

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 24 Jul 2026, 07:51 PM

OneSource Specialty Pharma has announced the resignation of Ravi Kumar, Global Head of Injectables and Corporate Strategy, effective July 24, 2026. To fill the Senior Management Personnel (SMP) gap, the company has designated Preeti Kalra, Head of Human Resources, as an SMP. This leadership transition occurs while the company is loss-making (TTM PAT of -₹49 Cr) and managing a significant debt of ₹1,504 Cr. The departure of the Injectables head is particularly relevant as the company targets capacity expansion in this segment by CY 2026.

Ravi Kumar resigned as Global Head – Injectables and Head of Corporate Strategy effective July 24, 2026.
Preeti Kalra, with over 25 years of experience in Biopharma and IT, designated as Senior Management Personnel.
Company maintains a TTM revenue of ₹1,422 Cr with a current debt-to-equity ratio of 0.25.
Injectables segment is critical with an installed capacity of 40 million units and expansion planned for CY 2026.

💡 Investors should monitor the announcement of a new head for the Injectables and Strategy division, as this role is vital for executing the integrated CDMO model and managing the 4 USFDA-approved facilities.

Onesource Specialty Pharma Q1 FY27 Results: Subsidiary Revenue at Rs 28.35 Cr

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 24 Jul 2026, 07:03 PM

Onesource Specialty Pharma Limited reported its Q1 FY27 results for the period ended June 30, 2026. While the full consolidated P&L was not detailed in the auditor's extract, two key subsidiaries contributed Rs 28.35 cr in revenue with a net loss of Rs 1.21 cr. The company is currently in a transition phase following the restructuring of CDMO businesses from Strides and Steriscience. With a TTM revenue of Rs 1,422 cr and a recent history of volatility (Mar 2026 PAT of Rs 4.6 cr vs Dec 2025 loss of Rs 88.7 cr), the market will focus on the consolidated margin trajectory.

Two subsidiaries reported a combined revenue of Rs 28.35 cr (Rs 283.47 million) for the quarter ended June 30, 2026.
Net loss from these two subsidiaries stood at Rs 1.21 cr (Rs 12.14 million) for the same period.
Four other subsidiaries reported Nil revenue and a combined loss of Rs 0.18 cr (Rs 1.79 million).
The company maintains 7 manufacturing facilities, 4 of which are USFDA approved, supporting its CDMO model.
Consolidated debt remains a factor at Rs 1,504 cr against a TTM revenue of Rs 1,422 cr.

💡 Investors should monitor the full consolidated financial statement to see if the company has maintained the slim profitability achieved in Mar 2026 (Rs 4.6 cr) or reverted to losses.

July 25 Earnings Call Scheduled for Q1FY27 Results

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 21 Jul 2026, 12:32 PM

Onesource Specialty Pharma has scheduled its Q1FY27 earnings call for July 25, 2026, to discuss unaudited financial results. This follows a period of recovery where the company reported a net profit of ₹4.6 Cr in Mar 2026, compared to a significant loss of ₹88.7 Cr in Dec 2025. Management, including CEO Neeraj Sharma and CFO Anurag Bhagania, will lead the discussion. Investors will likely look for updates on the integration of CDMO businesses and the progress of the 26 new RFP wins reported previously.

Earnings call scheduled for July 25, 2026, at 10:00 AM IST
Discussion to cover unaudited financial results for the quarter ended June 30, 2026
Senior management participation includes CEO Neeraj Sharma and CFO Anurag Bhagania
Company operates with a TTM revenue base of ₹1,422 Cr and a market cap of ₹12,963 Cr

💡 Monitor the call for management commentary on the GLP-1 launch timeline and the status of USFDA approvals for its 4 key facilities.

OneSource Partners with Formycon AG for Strategic Biosimilar Manufacturing in Bangalore

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 14 Jul 2026, 10:02 AM

OneSource Specialty Pharma has entered a strategic manufacturing partnership with Munich-based Formycon AG, a leading independent biosimilar developer. OneSource will provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing from its Bangalore facility, which is US FDA and EMA approved. Formycon currently has 3 biosimilars on the market and 4 candidates in its pipeline, including biosimilars for pembrolizumab and dupilumab. This partnership validates OneSource's biologics platform and provides a pathway to utilize its high-end manufacturing capacity for global markets.

OneSource to provide end-to-end Drug Substance and Drug Product manufacturing from its Bangalore biologics facility.
Formycon brings a portfolio of 3 marketed biosimilars and 4 pipeline candidates currently in development.
OneSource operates 5 manufacturing facilities approved by global regulatory authorities including the US FDA and EMA.
The company employs a dedicated team of over 1,600 professionals to support its global CDMO operations.
Formycon's pipeline includes high-value candidates like FYB206 (pembrolizumab) and FYB208 (dupilumab).

💡 Monitor the timeline for the commencement of commercial batches and the impact on capacity utilization at the Bangalore facility, which is key to reversing the current TTM net loss of Rs 49 Cr.

On eS o u r c e c l a r i f i e s n o m a t e r i a l i m p a c t f r o m D r . R e d d y ' s S e m a g l u t i d e s u p p l y d e l a y

🟡 NE U T R A L ⭐ 6/10

OT H E R 📅 09 Jul 2026, 10:49 AM

On eS o u r c e S p e c i a l t y P h a r m a h a s c l a r i f i e d t h a t t h e d e l a y i n c o m m e r c i a l s u p p l i e s o f S e m a g l u t i d e a n n o u n c e d b y i t s p a r t n e r , D r . R e d d y ’ s L a b o r a t o r i e s ( D R L ) , w i l l n o t h a v e a m a t e r i a l f i n a n c i a l i m p a c t . T h e c o m p a n y s t a t e d t h a t i t s e x i s t i n g c a p a c i t i e s a r e f u l l y c o m m i t t e d t o o t h e r c u s t o m e r s , i n c l u d i n g t h o s e i n C a n a d a . A d d i t i o n a l l y , O n e S o u r c e i s p r o c e e d i n g w i t h s i g n i f i c a n t c a p a c i t y e x p a n s i o n s t a r t i n g t h i s q u a r t e r ( J u l y 2 0 2 6 ) t o m e e t f u t u r e d e m a n d . T h i s c l a r i f i c a t i o n i s c r i t i c a l g i v e n t h e c o m p a n y ' s p r e v i o u s g u i d a n c e o n G L P - 1 p r o d u c t s b e i n g a k e y g r o w t h d r i v e r .

Con f i r m e d n o m a t e r i a l f i n a n c i a l i m p a c t f r o m D R L ' s S e m a g l u t i d e s u p p l y d e l a y
Cur r e n t m a n u f a c t u r i n g c a p a c i t i e s a r e f u l l y c o m m i t t e d t o o t h e r g l o b a l c u s t o m e r s
Sig n i f i c a n t n e w c a p a c i t y a d d i t i o n s c o m m e n c i n g i n t h e c u r r e n t q u a r t e r ( Q 2 F Y 2 7 )
Mai n t a i n s a c u s t o m e r b a s e o f m o r e t h a n 2 5 p l a y e r s t o m i t i g a t e c o n c e n t r a t i o n r i s k s

💡 In v e s t o r s s h o u l d m o n i t o r t h e e x e c u t i o n t i m e l i n e o f t h e n e w c a p a c i t y e x p a n s i o n d u e i n C Y 2 0 2 6 a n d t h e r e s u m p t i o n o f D R L ' s c o m m e r c i a l s u p p l y t i m e l i n e .

View All ONESOURCE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

OneSource reported H1 FY26 revenue of INR 7,030 million, representing a 12% YoY growth. The proforma combined revenue for H1 FY26 reached $110 million, driven by the integration of CDMO businesses from Strides and Steriscience.

Geographic Revenue Split

The company derives 100% of its revenue from international markets, with 50% specifically coming from the US market. Production is primarily based in India and exported to regulated, growth, and access markets.

Profitability Margins

In Q2 FY26, the company reported an adjusted PAT of INR 449 million. The company achieved a break-even PBILDT for the first time in Q4 FY24, following a net loss of INR 391 crores in FY24 and INR 800 crores in FY23.

EBITDA Margin

EBITDA margin for Q2 FY26 expanded to 28%, a 506 basis point improvement YoY. Proforma combined EBITDA margin for H1 FY26 stood at 30% ($33 million EBITDA on $110 million revenue).

Capital Expenditure

The company is utilizing proceeds from a pre-listing fundraise for capex to add new capacity, with a typical lead time of two years. New capacity is expected to be operational by calendar year 2026.

Credit Rating & Borrowing

CARE Ratings reaffirmed ratings, noting that net debt to PBILDT is expected to fall below 2.5x by March 2025. Net debt for the incoming business stands at $11.5 million as of September 30, 2025, trending toward $7-$8 million.

⚙️ Operational Drivers

Import Sources

Production is centered in India, with finished products exported to overseas subsidiaries for sale in approximately 100 countries.

Capacity Expansion

Current installed capacity for the DDC (Sterile Injectables) business is 40 million units, with deliverable capacity ranging between 15 million to 20 million units. Expansion is planned for completion in CY 2026.

Raw Material Costs

Raw material price volatility contributed to margin moderation in FY22. The company uses natural hedges and forward covers to mitigate these costs and forex fluctuations.

Manufacturing Efficiency

Working capital utilization was at 90% for the 12 months ending April 2024. The company operates 7 manufacturing facilities, 4 of which are US FDA approved.

Logistics & Distribution

Distribution spans approximately 100 countries, with significant exposure to regulated markets like the USA and UK.

📈 Strategic Growth

Expected Growth Rate

12%

Growth Strategy

Growth will be achieved through an integrated CDMO model combining Biologics, Sterile Injectables, and Softgel. Strategies include cross-selling (12 common customers across modalities), 26 new RFP wins in a single quarter, and a material profit-share partnership with NATCO for first-to-file opportunities.

Products & Services

CDMO services for Biologics, Sterile Injectables, Softgel, and GLP-1 products.

Brand Portfolio

OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited).

New Products/Services

First Commercial Service Agreement (CSA) for a GLP-1 launch expected in FY25; 26 new RFPs added in the most recent quarter.

Market Expansion

Expansion into 100 countries with a focus on regulated markets; non-Canadian markets expected to open up from April 2026.

Strategic Alliances

Partnership with NATCO for profit-sharing on first-to-file SKUs; backing from global and local PE players.

🌍 External Factors

Industry Trends

The CDMO industry is evolving toward integrated service providers. OneSource is positioning itself as a single-source partner for Biologics and complex injectables to capture higher wallet share.

Competitive Landscape

Competes with established global CDMO players; currently has a moderate size and requires volume growth for operational efficiencies.

Competitive Moat

Moat is built on 4 USFDA-approved facilities, an integrated 'OneSource' modality model that encourages cross-selling, and a 2-year lead time barrier for competitors to add similar sterile capacity.